Loading…
Loading…
did you talk about talk to OpEx within your FY 2027 guidance? I'm only asking because it looks like R&D stepped up
The SG&A growth is uncharacteristically ahead of revenue growth
I'm not sure you actually gave us your thoughts on what you think the range of outcomes will be
can you just talk through the elements of that gross margin guidance? And maybe touch on the FX
I was just wondering if that exemption will apply or extend to all CPAP and therapy coming into the US
Can you just talk us through any other FX impacts down the P&L as we've seen the strength of the U.S. dollar?
we've noticed that this term tuck-in acquisition has become very common in your commentary